Use of Induced Pluripotent Cells and other Cells for Screening Compound Libraries

• US 20110237535A1
• Filed: 03/28/2011
• Published: 09/29/2011
• Est. Priority Date: 03/26/2010
• Status: Abandoned Application

• Current Assignee: X-Body Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Sru Biosystems Incorporated
• Inventors: Yuzhakov, Alexander, Wagner, Rick, Shamah, Steven, Sandberg, Eric
• Application Number:
  US13/073,233
• Publication Number:
  US 20110237535A1
• Time in Patent Office: Days
• US Class Current: 514/34
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 33/5014 for testing toxicity
• CPC Class Codes: G01N 33/5058 Neurological cells
• CPC Class Codes: G01N 33/5061 Muscle cells
• CPC Class Codes: G01N 33/5088 of vertebrates

Abstract

The invention provides methods for screening test compounds or toxins for effects on cells. The invention also provides methods for determining frequency, amplitude and kinetic profiles of cells.

Claims

1. A method for screening a compound or environmental condition for an effect on cells, cell aggregates, or tissue comprising:

(a) applying the cells, cell aggregates, or tissue to a colorimetric resonant reflectance biosensor surface, a dielectric film stack biosensor surface, or a grating-based waveguide biosensor surface;

(b) contacting the cells, cell aggregates, or tissue with the compound or environmental condition;

(c) detecting periodic or continuous peak wavelength values or effective refractive index values during a time course;

(d) analyzing the peak wavelength values or effective refractive index values for frequency, amplitude, or kinetic profile, or a combination thereof over the time course;

wherein a change in frequency, amplitude, or kinetic profile after the compound or environmental condition is contacted with the cells, cell aggregates, or tissue indicates that the compound or environmental condition has an effect on the cells, cell aggregates, or tissue.

2. The method of claim 1, wherein two or more concentrations of the compound are added to one or more populations the cells, cell aggregates, or tissue at two or more distinct locations on the biosensor surface.

3. The method of claim 1, wherein the cells are stem cells, human or mammalian induced pluripotent stem cells, cells differentiated from the human or mammalian induced pluripotent cells, neural stem cells, neurons, cardiomyocyte stem cells, cardiomyocytes, hepatic stem cells, hepatocytes. or combinations thereof.

4. The method of claim 3, wherein the human or mammalian induced pluripotent stem cell line, or cells differentiated from the human or mammalian induced pluripotent cells are cardiomyocytes.

5. The method of claim 1, wherein the peak wavelength values or effective refractive index values are analyzed for frequency or amplitude, wherein a decreased frequency over the time course of the assay indicates a negative effect of the compound or environmental condition on the cells, cell aggregates, or tissue, and wherein a decreased amplitude over the time course of the assay indicates a negative effect of the compound or environmental condition on the cells, cell aggregates or tissue.

6. The method of claim 2, wherein the peak wavelength values or effective refractive index values are analyzed for frequency or amplitude, wherein a decreased frequency with increasing compound concentration indicates a negative effect of the compound on the cells, cell aggregates, or tissue and wherein a decreased amplitude with increasing compound concentration indicates a negative effect of the compound or environmental condition on the cells, cell aggregates, or tissue.

7. The method of claim 1, wherein the peak wavelength values are analyzed for kinetic profile, wherein a kinetic profile that moves from a positive peak wavelength value to a negative peak wavelength value over the time course indicates a negative effect of the compound or environmental condition on the cells, cell aggregates, or tissue.

8. The method of claim 2, wherein the peak wavelength values are analyzed for kinetic profile, wherein a kinetic profile that moves from a positive peak wavelength value to a negative peak wavelength value with increasing concentration of the compound indicates a negative effect of the compound or environmental condition on the cells, cell aggregates, or tissue.

9. The method of claim 1, wherein the compound is a drug, a calcium channel blocker, a β

-adrenoreceptor agonist, an α

-adrenoreceptor agonist, test reagent, a polypeptide, a polynucleotide, a modifier of a hERG channel, or a toxin.

10. The method of claim 1, wherein the cell aggregates are embroid bodies.

15. The method of claim 1, wherein said contacting step further includes contacting the cells, cell aggregates, or tissue with at least one second compound or at least one second environmental condition in the presence of the first compound or the first environmental condition.

11. A method for reducing the risk of pharmacological agent toxicity in a subject, comprising:

(a) contacting one or more cells differentiated from an induced pluripotent stem cell line generated from the subject with a dose of a pharmacological agent;

(b) assaying the contacted one or more cells for toxicity comprising;

(i) applying the cells to a colorimetric resonant reflectance biosensor surface, a dielectric film stack biosensor surface, or a grating-based waveguide biosensor surface;

(ii) contacting the cells with the pharmacological agent;

(iii) detecting periodic or continuous peak wavelength values or effective refractive index values during a time course;

(iv) analyzing the peak wavelength values or effective refractive index values for frequency, amplitude, or kinetic profile or a combination thereof over the time course;

wherein a negative change in frequency, amplitude, or kinetic profile after the pharmacological agent is contacted with the cells indicates that the pharmacological agent has a negative toxicity effect on the cells;

(c) prescribing or administering the pharmacological agent to the subject only if the pharmacological agent does not have a negative toxicity effect on the contacted cells, thereby reducing the risk of pharmacological toxicity in a subject.

12. A method for reducing the risk of pharmacological agent toxicity in a subject, comprising:

(a) contacting one or more cell populations differentiated from an induced pluripotent stem cell line generated from the subject with two or more dose concentrations of a pharmacological agent;

(b) assaying the contacted one or more cell populations for toxicity comprising;

(i) applying the one or more cell populations to a colorimetric resonant reflectance biosensor surface, a dielectric film stack biosensor surface or a grating-based waveguide biosensor surface;

(ii) contacting the one or more cell populations with two of more concentrations the pharmacological agent;

(iii) detecting one or more peak wavelength values or effective refractive index values for each concentration of the pharmacological agent;

(iv) analyzing the peak wavelength values or effective refractive index values for frequency, amplitude, or kinetic profile or a combination thereof for each concentration of the pharmacological agent;

wherein a negative change in frequency, amplitude, or kinetic profile after the pharmacological agent is contacted with the cells indicates that the pharmacological agent concentration has a negative toxicity effect on the cells;

(c) prescribing or administering the pharmacological agent to the subject only if the pharmacological agent concentration does not have a negative toxicity effect in the contacted cells, thereby reducing the risk of pharmacological toxicity in a subject.

13. A method of screening a compound for neutralizing activity on a toxin or negative environmental condition comprising:

(a) applying cells, cell aggregates, or tissue to a colorimetric resonant reflectance biosensor surface, a dielectric film stack biosensor surface, or a grating-based waveguide biosensor surface;

(b) contacting the cells, cell aggregates, or tissue with the toxin or negative environmental condition and the compound;

(c) detecting periodic or continuous peak wavelength values or effective refractive index values during a time course;

(d) analyzing peak wavelength values or effective refractive index values for frequency, amplitude, or kinetic profile or a combination thereof over the time course;

wherein a positive change in frequency, amplitude, or kinetic profile after the compound is contacted with the cells, cell aggregates, or tissue indicates that the compound has a neutralizing effect on the toxin or negative environmental condition.

14. A method of screening a compound for neutralizing activity on a toxin or negative environmental condition comprising:

(a) applying one or more cells, cell aggregates, or tissue populations to a colorimetric resonant reflectance biosensor surface, a dielectric film stack biosensor surface, or a grating-based waveguide biosensor surface;

(b) contacting the one or more cells, cell aggregates, or tissue populations with the toxin or negative environmental condition and the compound at two or more compound concentrations;

(c) detecting periodic or continuous peak wavelength values or effective refractive index values during a time course for each compound concentration;

(d) analyzing peak wavelength values or effective refractive index values for frequency, amplitude, or kinetic profile or a combination thereof for each compound concentration over the time course;

wherein a positive change in frequency, amplitude, or kinetic profile after the compound is contacted with the cells, cell aggregates, or tissue indicates that the compound has a neutralizing effect on the toxin or negative environmental condition.

16. A method of screening a test toxin for a signature kinetic profile to determine a class or subclass of the test toxin comprising:

(a) applying cells, cell aggregates, or tissue to a colorimetric resonant reflectance biosensor surface, a dielectric film stack biosensor surface, or a grating-based waveguide biosensor surface;

(b) contacting the cells, cell aggregates, or tissue with the test toxin;

(c) detecting periodic or continuous peak wavelength values or effective refractive index values during a time course of the assay;

(d) analyzing the peak wavelength values or effective refractive index values for frequency, amplitude, or kinetic profile or a combination thereof over the time course of the assay to generate a signature kinetic profile of the test toxin'"'"'s effects on the cells, cell aggregates, or tissue; and

(e) comparing the signature kinetic profile of the test toxin to signature kinetic profiles of known toxins, wherein the test toxin is placed into a class or subclass of toxins having a similar signature kinetic profile as the test toxin.

17. A method for determining the effect of a test compound or environmental condition on the sinus rhythm of cardiomyocytes compromising:

(a) applying the cardiomyocytes to a colorimetric resonant reflectance biosensor surface, a dielectric film stack biosensor surface, or a grating-based waveguide biosensor surface;

(b) contacting the cardiomyocytes with the compound or environmental condition;

(c) detecting periodic or continuous peak wavelength values or effective refractive index values during a time course;

(d) analyzing the peak wavelength values or effective refractive index values for sinus rhythm over the time course;

wherein a change in the sinus rhythm after the compound or environmental condition is contacted with the cardiomyocytes indicates that the compound or environmental condition has an effect on the sinus rhythm of the cardiomyocytes.

18. The method of claim 17, wherein the effect of the test compound or environmental condition on the sinus rhythm is a prolongation or shortening of the QT interval.

19. A method for determining a beat or burst pattern of cardiac or neuronal cells, cardiac or neuron cell aggregates, or cardiac or neuronal tissue comprising:

(a) applying the cells, cell aggregates, or tissue to a colorimetric resonant reflectance biosensor surface, a dielectric film stack biosensor surface, or a grating-based waveguide biosensor surface;

(b) detecting periodic or continuous peak wavelength values or effective refractive index values during a time course;

(c) analyzing the peak wavelength values or effective refractive index values for frequency, amplitude, or kinetic profile, or a combination thereof over the time course;

wherein a beat or burst pattern of the cardiac or neuronal cells, cardiac or neuron cell aggregates, or cardiac or neuronal tissue is determined.

20. The method of claim 19, wherein one or more compounds are added to the cells, cell aggregates, or tissue before or after they are applied to the biosensor surface.